Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Madrigal Pharmaceuticals | 14.44 Bn | 14.20 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.59% |
| Dec 31, 2025 | 50.61% |
| Sep 30, 2025 | -33.15% |
| Jun 30, 2025 | 19.84% |
| Mar 31, 2025 | 26.57% |
| Dec 31, 2024 | -9.47% |
| Sep 30, 2024 | -55.73% |
| Jun 30, 2024 | -39.86% |
| Mar 31, 2024 | 97.55% |
| Dec 31, 2023 | -75.17% |
| Sep 30, 2023 | 17.36% |
| Jun 30, 2023 | 45.95% |
| Mar 31, 2023 | -12.84% |
| Dec 31, 2022 | 61.27% |
| Sep 30, 2022 | 42.41% |
| Jun 30, 2022 | 99.66% |
| Mar 31, 2022 | 48.81% |
| Dec 31, 2021 | 9.19% |
| Sep 30, 2021 | 26.82% |
| Jun 30, 2021 | -3.79% |
| Mar 31, 2021 | -28.44% |
| Dec 31, 2020 | -19.46% |
| Sep 30, 2020 | 32.03% |
| Jun 30, 2020 | 23.23% |
| Mar 31, 2020 | 43.42% |
| Dec 31, 2019 | -100.99% |
| Sep 30, 2019 | 22.82% |
| Jun 30, 2019 | 25.99% |
| Mar 31, 2019 | -17.25% |
| Dec 31, 2018 | 29.55% |
| Sep 30, 2018 | -94.93% |
| Jun 30, 2018 | -44.71% |
| Mar 31, 2018 | -22.77% |
| Sep 30, 2017 | -0.51% |
| Jun 30, 2017 | 41.72% |
| Mar 31, 2017 | 4.54% |
| Dec 31, 2016 | -12.80% |
| Sep 30, 2016 | 12.75% |
| Jun 30, 2016 | -9.88% |
| Mar 31, 2016 | 55.15% |
| Dec 31, 2015 | 90.50% |
| Sep 30, 2015 | 30.50% |